Donghee Kim, Su‐Yeon Choi, Eun Ha Park, Whal Lee, Jin Hwa Kang, Won Kim, Yoon Jun Kim, Jung‐Hwan Yoon, Sook Hyang Jeong, Dong Ho Lee, Hyo‐suk Lee, Joseph Larson, Terry M. Therneau, W. Ray Kim – 23 January 2012 – Nonalcoholic fatty liver disease (NAFLD) is related to risk factors of coronary artery disease, such as dyslipidemia, diabetes, and metabolic syndrome, which are closely linked with visceral adiposity.
Jennifer C. Lai, Jacqueline G. O'Leary, James F. Trotter, Elizabeth C. Verna, Robert S. Brown, R. Todd Stravitz, Jeffrey D. Duman, Lisa M. Forman, Norah A. Terrault, for the Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH‐C) – 23 January 2012 – Over the last decade, the use of liver grafts from hepatitis C virus antibody–positive donors [HCV(+)Ds] has tripled in the United States. Although previous studies have demonstrated no association between an HCV(+)D status and graft loss, the effects of an HCV(+)D on histological outcomes are not well known.
Yasunari Ohno, Akira Kobayashi, Toshihiko Ikegami, Yuichi Masuda, Atsuyoshi Mita, Koichi Urata, Yuichi Nakazawa, Masaru Terada, Shu‐ichi Ikeda, Shinichi Miyagawa – 23 January 2012 – To introduce duct‐to‐duct biliary anastomosis to conventional temporary auxiliary partial orthotopic liver transplantation (APOLT) using living donor graft for patients with familial amyloid polyneuropathy, we modified the conventional APOLT procedure in a manner characterized by the use of the recipient's common hepatic duct for biliary reconstruction and the preservation of the right posterior section alone fo
Keiichi Fujiwara, Osamu Yokosuka – 23 January 2012
Eric S. Orman, Paul H. Hayashi, Evan S. Dellon, David A. Gerber, A. Sidney Barritt – 23 January 2012 – Safety concerns have been raised about nighttime and weekend patient care, but it is unknown whether these issues affect liver transplantation. We sought to identify the impact of nighttime and weekend liver transplants on graft and patient survival. We used the United Network for Organ Sharing database to review adult liver transplants from 1987 to 2010. Comparisons were made between nighttime and daytime operations and between weekday and weekend operations.
Karin Hoppe‐Seyler, Peter Sauer, Claudia Lohrey, Felix Hoppe‐Seyler – 23 January 2012 – The inhibitors of pyrimidine synthesis, leflunomide and FK778, have been reported to exert broad antiviral effects, in addition to their immunosuppressive activities. Their possible therapeutic benefit for transplantation medicine is currently discussed, because they also block the replication of human cytomegalovirus and human polyomavirus BK, which both cause important complications in transplant recipients.
Cristina Rigamonti, Mirella Fraquelli, Anan Judina Bastiampillai, Lucio Caccamo, Paolo Reggiani, Giorgio Rossi, Massimo Colombo, Maria Francesca Donato – 23 January 2012 – Transient elastography (TE) reliably predicts the severity of recurrent hepatitis C virus after orthotopic liver transplantation (OLT); however, its accuracy in evaluating nonviral liver graft damage is unknown.
Leandro C. Mosna, Jang Moon, Francisco Hernandez, Peter Hodgkinson, Ji Fan, Gennaro Selvaggi, Akin Tekin, Seigo Nishida, David Levi, Andreas G. Tzakis – 23 January 2012
Joao Seda Neto, Renata Pugliese, Eduardo A. Fonseca, Rodrigo Vincenzi, Vincenzo Pugliese, Helry Candido, Alberto B. Stein, Marcel Benavides, Bernardo Ketzer, Hsiang Teng, Gilda Porta, Irene K. Miura, Vera Baggio, Teresa Guimaraes, Adriana Porta, Celso Arrais Rodrigues, Francisco C. Carnevale, Eduardo Carone, Mario Kondo, Paulo Chapchap – 23 January 2012 – The availability of living donors allows transplant teams to indicate living donor liver transplantation (LDLT) early in the course of liver disease before the occurrence of life‐threatening complications.
Ning Li, Lei Zhang, Liangwei Chen, Wenfeng Feng, Yinfeng Xu, Feng Chen, Xiaohong Liu, Zhi Chen, Wei Liu – 23 January 2012 – Human MxA, an interferon‐inducible cytoplasmic dynamin‐like GTPase, possesses antiviral activity against multiple RNA viruses. Recently, MxA has also been demonstrated to have activity against the hepatitis B virus (HBV), a well‐known DNA virus responsible for acute and chronic liver disease in humans. We investigated the molecular mechanism for the anti‐HBV activity of MxA.